232 related articles for article (PubMed ID: 37468332)
1. Finerenone.
Vachek J; Tesař V
Vnitr Lek; 2023; 69(E-3):20-23. PubMed ID: 37468332
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
4. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
6. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
7. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].
Scheen A; Delanaye P
Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038
[TBL] [Abstract][Full Text] [Related]
8. Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM.
Long A; Salvo M
Ann Pharmacother; 2022 Sep; 56(9):1041-1048. PubMed ID: 35021925
[TBL] [Abstract][Full Text] [Related]
9. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
[TBL] [Abstract][Full Text] [Related]
12. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Lerma EV; Wilson DJ
Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
Solis-Herrera C; Triplitt C
Diabetes Obes Metab; 2024 Feb; 26(2):417-430. PubMed ID: 37885354
[TBL] [Abstract][Full Text] [Related]
14. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
15. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Ding K; Li Z; Lu Y; Sun L
Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
[TBL] [Abstract][Full Text] [Related]
17. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
DeFronzo RA; Bakris GL
Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
[TBL] [Abstract][Full Text] [Related]
18. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
Raj R
Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
20. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease.
Górriz JL; González-Juanatey JR; Facila L; Soler MJ; Valle A; Ortiz A
Nefrologia (Engl Ed); 2023; 43(4):386-398. PubMed ID: 37813743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]